AU2017350947B2 - Anti-ApoE antibodies - Google Patents

Anti-ApoE antibodies Download PDF

Info

Publication number
AU2017350947B2
AU2017350947B2 AU2017350947A AU2017350947A AU2017350947B2 AU 2017350947 B2 AU2017350947 B2 AU 2017350947B2 AU 2017350947 A AU2017350947 A AU 2017350947A AU 2017350947 A AU2017350947 A AU 2017350947A AU 2017350947 B2 AU2017350947 B2 AU 2017350947B2
Authority
AU
Australia
Prior art keywords
seq
ser
antibody
apoe
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017350947A
Other languages
English (en)
Other versions
AU2017350947A1 (en
Inventor
Thu Nga Bien-Ly
Mark S. Dennis
Jing Guo
David Holtzman
Hong Jiang
Fan LIAO
Adam P. Silverman
Ryan J. Watts
Yin Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
Original Assignee
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University in St Louis WUSTL filed Critical Washington University in St Louis WUSTL
Publication of AU2017350947A1 publication Critical patent/AU2017350947A1/en
Assigned to WASHINGTON UNIVERSITY reassignment WASHINGTON UNIVERSITY Request for Assignment Assignors: DENALI THERAPEUTICS INC., WASHINGTON UNIVERSITY
Application granted granted Critical
Publication of AU2017350947B2 publication Critical patent/AU2017350947B2/en
Priority to AU2024203123A priority Critical patent/AU2024203123A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2017350947A 2016-10-28 2017-10-27 Anti-ApoE antibodies Active AU2017350947B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024203123A AU2024203123A1 (en) 2016-10-28 2024-05-10 Anti-ApoE antibodies

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662414413P 2016-10-28 2016-10-28
US62/414,413 2016-10-28
US201762533336P 2017-07-17 2017-07-17
US62/533,336 2017-07-17
PCT/US2017/058874 WO2018081642A1 (en) 2016-10-28 2017-10-27 Anti-apoe antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024203123A Division AU2024203123A1 (en) 2016-10-28 2024-05-10 Anti-ApoE antibodies

Publications (2)

Publication Number Publication Date
AU2017350947A1 AU2017350947A1 (en) 2019-05-16
AU2017350947B2 true AU2017350947B2 (en) 2024-02-15

Family

ID=62024064

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017350947A Active AU2017350947B2 (en) 2016-10-28 2017-10-27 Anti-ApoE antibodies
AU2024203123A Pending AU2024203123A1 (en) 2016-10-28 2024-05-10 Anti-ApoE antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024203123A Pending AU2024203123A1 (en) 2016-10-28 2024-05-10 Anti-ApoE antibodies

Country Status (6)

Country Link
US (4) US11124562B2 (enExample)
EP (1) EP3532034A4 (enExample)
JP (3) JP7236737B2 (enExample)
AU (2) AU2017350947B2 (enExample)
CA (1) CA3042236A1 (enExample)
WO (1) WO2018081642A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11124562B2 (en) 2016-10-28 2021-09-21 Washington University Anti-ApoE antibodies
US20220296707A1 (en) * 2019-06-04 2022-09-22 Regents Of The University Of Minnesota Anti-opioid compounds and methods of making and using same
CN112538113B (zh) * 2020-08-06 2023-07-21 武汉天德生物科技有限公司 杂交瘤细胞株ace8及其产生的apoe4点突变单克隆抗体
EP4204003A4 (en) * 2020-08-28 2024-08-21 Board of Regents, The University of Texas System ANTIBODIES SPECIFIC TO CCL21 AND METHODS OF USE
EP4286406A4 (en) 2021-01-29 2025-07-23 Illimis Therapeutics Inc FUSION MOLECULE WITH NON-INFLAMMATORY PHAGOCYTOSIS-INDUCING ACTIVITY
WO2023069892A1 (en) * 2021-10-19 2023-04-27 Short Jay M Conditionally active proteins for neurodegenerative diseases
WO2025049995A1 (en) * 2023-09-01 2025-03-06 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Anti-ly6 antibodies and uses thereof
WO2025219956A1 (en) 2024-04-18 2025-10-23 Comed Therapeutics Ltd. Compositions and methods for rna delivery to cells
CN118184783B (zh) * 2024-05-09 2024-07-09 成都微芯新域生物技术有限公司 Hla-g抗体及其制备方法和用途
CN119147750A (zh) * 2024-11-15 2024-12-17 科美诊断技术股份有限公司 一种apoe4的光激化学发光检测试剂、试剂盒及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003060158A2 (en) * 2002-01-15 2003-07-24 The University Of Manchester Institute Of Science And Technology Apoe genotype as a prognostic marker for hepatitis
US20150118231A1 (en) * 2012-05-08 2015-04-30 Ramot At Tel-Aviv University Ltd. Apoe4 antibodies for treatment of neurodegenerative conditions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US6313089B1 (en) 1997-08-20 2001-11-06 Duke University Complexes of apolipoprotein E and ciliary neurotrophic factor (CNTF) and methods of use
KR100767146B1 (ko) * 2000-02-24 2007-10-15 워싱톤 유니버시티 Ａβ 펩티드를 격리시키는 인간화 항체
WO2001072307A1 (en) * 2000-03-29 2001-10-04 The J. David Gladstone Institutes Methods of treating cognitive decline disease conditions with androgens
US7754433B2 (en) * 2001-12-03 2010-07-13 Amgen Fremont Inc. Identification of high affinity molecules by limited dilution screening
AR047729A1 (es) 2003-11-28 2006-02-15 Astrazeneca Ab Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe)
CA2672049C (en) 2006-12-08 2016-05-10 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angptl3
DE102009047243A1 (de) * 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien
US9102717B2 (en) * 2010-03-01 2015-08-11 The J. David Gladstone Institutes Antibody specific for apolipoprotein and methods of use thereof
RU2013130002A (ru) 2010-12-02 2015-01-10 Дзе Вашингтон Юниверсити Композиции и способы лечения симптомов, ассоциированных с амилоидными бляшками
JP2014511174A (ja) * 2011-02-07 2014-05-15 ネオトープ バイオサイエンシーズ リミテッド Ａｐｏｅ免疫療法
CA2859808A1 (en) 2011-12-19 2013-06-27 The Washington University Methods for diagnosing alzheimer's disease
US20150140672A1 (en) 2011-12-19 2015-05-21 Washington University Methods for detecting amyloid beta amyloidosis
CA2890758A1 (en) 2012-11-20 2014-05-30 Washington University Methods of diagnosing amyloid pathologies using analysis of amyloid-beta enrichment kinetics
WO2015187992A2 (en) * 2014-06-05 2015-12-10 The Regents Of The University Of Colorado, A Body Corporate Map44 polypeptides and constructs based on natural antibodies and uses thereof
US20170218058A1 (en) 2016-01-28 2017-08-03 Alector, LLC Anti-apoe4 antigen-binding proteins and methods of use thereof
US11124562B2 (en) * 2016-10-28 2021-09-21 Washington University Anti-ApoE antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003060158A2 (en) * 2002-01-15 2003-07-24 The University Of Manchester Institute Of Science And Technology Apoe genotype as a prognostic marker for hepatitis
US20150118231A1 (en) * 2012-05-08 2015-04-30 Ramot At Tel-Aviv University Ltd. Apoe4 antibodies for treatment of neurodegenerative conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ISHAI LUZ ET AL: "An Anti-apoE4 Specific Monoclonal Antibody Counteracts the Pathological Effects of apoE4 In Vivo", CURRENT ALZHEIMER RESEARCH, vol. 13, no. 8, 2 June 2016 (2016-06-02), NL, pages 918 - 929 *

Also Published As

Publication number Publication date
EP3532034A4 (en) 2020-12-02
JP2020506162A (ja) 2020-02-27
US11124562B2 (en) 2021-09-21
JP2025023998A (ja) 2025-02-19
EP3532034A1 (en) 2019-09-04
AU2024203123A1 (en) 2024-05-30
US20220411485A1 (en) 2022-12-29
US11926660B2 (en) 2024-03-12
US20190270794A1 (en) 2019-09-05
US20240309077A1 (en) 2024-09-19
JP2022191397A (ja) 2022-12-27
AU2017350947A1 (en) 2019-05-16
US20250145697A1 (en) 2025-05-08
JP7236737B2 (ja) 2023-03-10
CA3042236A1 (en) 2018-05-03
WO2018081642A1 (en) 2018-05-03

Similar Documents

Publication Publication Date Title
US11926660B2 (en) Anti-ApoE antibodies
US12145988B2 (en) Anti-TREM-2 agonist antibodies
AU2016292892A1 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
CN105979962A (zh) 使用抗Aβ抗体减少脑淀粉样蛋白斑块的方法
CN114206444A (zh) 用于治疗和诊断的新分子
US20230174669A1 (en) Anti-CD98 Antibodies And Uses Thereof
CN116348487A (zh) 抗淀粉样β抗体
JP2024512589A (ja) 抗タウ抗体及びその使用
US20200385461A1 (en) Fusion constructs and uses thereof
US20250163136A1 (en) Anti-transthyretin (ttr) binding proteins and uses thereof
EP4652204A2 (en) Lilrb4/ilt3 antagonist compositions and methods of use thereof
CN120858110A (zh) 用抗Aβ抗体治疗神经病症的方法
EA047298B1 (ru) Антитела к phf-тау и их применение
HK40071061A (en) Novel molecules for therapy and diagnosis

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: WASHINGTON UNIVERSITY

Free format text: FORMER APPLICANT(S): WASHINGTON UNIVERSITY; DENALI THERAPEUTICS INC.

FGA Letters patent sealed or granted (standard patent)